Robin Norris, MD, MS, MPH
- Director, Clinical Research for Oncology, Division of Oncology
- Co-Director, Young Adult Oncology Program, Division of Oncology
- Associate Professor, UC Department of Pediatrics
- robin.norris@cchmc.org
- Board Certified
About
BA: Human Biology, Stanford University, Stanford, CA, 1997.
MD: University of Pennsylvania School of Medicine, Philadelphia, PA, 2001.
MPH: Epidemiology, University of California, Berkeley, CA, 2005.
MS: Translational Research, University of Pennsylvania School of Medicine, Institute for Translational Medicine and Therapeutics, Philadelphia, PA, 2010.
Intern: Pediatrics, University of California, San Francisco, CA, 2001-2002.
Resident: Pediatrics, University of California, San Francisco, CA, 2002-2004.
Fellow: Pediatric Hematology/Oncology, The Children’s Hospital of Philadelphia, Philadelphia, CA, 2005-2008.
Services and Specialties
Cancer and Blood Diseases, Leukemia, Young Adult Cancer
Research Areas
Cancer and Blood Diseases, Oncology
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Feasibility pilot trial of a tailored medication adherence-promotion intervention for adolescents and young adults with cancer: Study design and protocol. Contemporary Clinical Trials. 2024; 139:107483.
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1). Pediatric Blood and Cancer. 2023; 70:e30609.
Clinical trials: A plea to cooperative groups, consortia, pharmaceutical companies, and lead investigators for reasonable imaging protocols. Pediatric Blood and Cancer. 2023; 70:e30362.
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Advances. 2023; 7:3225-3231.
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and Cellular Therapy. 2023; 29:311.e1-311.e7.
Barriers to medication adherence among adolescents and young adults with cancer. Pediatric Blood and Cancer. 2023; 70:e30186.
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Advances. 2023; 7:602-610.
Adherence and Barriers to Inpatient Physical Therapy Among Adolescents and Young Adults with Hematologic Malignancies. Journal of Adolescent and Young Adult Oncology. 2022; 11:605-610.
P1088: UPDATED DATA FROM A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN COMBINED WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA. HemaSphere. 2022; 6:978-979.
Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis. Blood. 2021; 138:2465.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey